TCF3

Across TCGA pan-cancer cohorts, TCF3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TCF3 data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher TCF3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TCF3 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, HNSC, and LUAD are the cancer types where TCF3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	All	0.926	0.712	<.001	32	view →
HNSC	OS	Quartile	IV	0.738	1.000	.002	19	view →
LUAD	DFS	Median	All	0.949	0.840	.011	10	view →
PDAC	DFS	Median	IV	0.934	0.235	.024	6	view →
GBM	DFS	Median	All	0.674	0.815	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TCF3–LSCC (OS)

Open the LSCC breakdown →